Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Docetaxel (Primary) ; Pembrolizumab (Primary)
- Indications Salivary gland cancer; Thyroid cancer
- Focus Therapeutic Use
- Acronyms The iPRIME Study
- 29 Jul 2024 According to ClinicalTrials.gov, this trial is suspended as Per PI. Cohorts are closed for analysis
- 29 Jul 2024 Status changed from recruiting to suspended.
- 14 Feb 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2032.